Ra Capital Management, L.P. sold $63.5M of Septerna (SEPN)

Executed Aug 12, disclosed Aug 14, 2 days later.

Value, as filed

$63.5M

1,493,000 sh across 2 lots

Executed

Aug 12

the trade date, as filed

Disclosed

Aug 14

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

RP Ra Capital Management, L.P. Director profile →

Ra Capital Management, L.P. (Director) filed 30 Form 4 reports as a reporting entity in the trailing twelve months (23 purchases, 7 sales, 1 filed past the two-business-day deadline), most often in Artiva Biotherapeutics, Inc. (ARTV). Across 23 priced purchase filings, the average 21-session return was +14.9% from execution and +14.0% from disclosure (delay-adjusted; derived). The largest single filing was $423.8M of PBLS (21,188,750 sh across 2 lots, as filed), executed Jun 11.

The name

SEPN

Septerna, Inc. SEPN · Healthcare · 13 filings in 24 months ticker →

Healthcare · Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule produc…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→